DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents

被引：0
|
作者：
J P B O'Connor
A Jackson
G J M Parker
G C Jayson
机构：
[1] Imaging Science and Biomedical Engineering,Cancer Research UK Department of Medical Oncology
[2] University of Manchester,undefined
[3] Christie Hospital,undefined
来源：
British Journal of Cancer | 2007年 / 96卷
关键词：
angiogenesis inhibitors; biomarkers; clinical trials; dynamic contrast-enhanced magnetic resonance imaging; image analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is now frequently used in early clinical trial assessment of antiangiogenic and vascular disrupting compounds. Evidence of drug efficacy and dose-dependent response has been demonstrated with some angiogenesis inhibitors. This review highlights the critical issues that influence T1-weighted DCE-MRI data acquisition and analysis, identifies important areas for future development and reviews the clinical trial findings to date.
引用
收藏
页码：189 / 195
页数：6
相关论文
共 50 条
  • [1] DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents
    O'Connor, J. P. B.
    Jackson, A.
    Parker, G. J. M.
    Jayson, G. C.
    BRITISH JOURNAL OF CANCER, 2007, 96 (02) : 189 - 195
  • [2] Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI
    Kyung Won Kim
    Jeong Min Lee
    Yong Sik Jeon
    In Joon Lee
    YoonSeok Choi
    Jisuk Park
    Berthold Kiefer
    Chin Kim
    Joon Koo Han
    Byung Ihn Choi
    Investigational New Drugs, 2013, 31 : 1097 - 1106
  • [3] Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI
    Kim, Kyung Won
    Lee, Jeong Min
    Jeon, Yong Sik
    Lee, In Joon
    Choi, YoonSeok
    Park, Jisuk
    Kiefer, Berthold
    Kim, Chin
    Han, Joon Koo
    Choi, Byung Ihn
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1097 - 1106
  • [4] Assessment of Vascular Remodeling Under Antiangiogenic Therapy Using DCE-MRI and Vessel Size Imaging
    Zwick, Stefan
    Strecker, Ralph
    Kiselev, Valerji
    Gall, Peter
    Huppert, Jochen
    Palmowski, Moritz
    Lederle, Wiltrud
    Woenne, Eva C.
    Hengerer, Arne
    Taupitz, Matthias
    Semmler, Wolfhard
    Kiessling, Fabian
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2009, 29 (05) : 1125 - 1133
  • [5] Erratum to: Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI
    Kyung Won Kim
    Jeong Min Lee
    Yong Sik Jeon
    In Joon Lee
    YoonSeok Choi
    Jisuk Park
    Berthold Kiefer
    Chin Kim
    Joon Koo Han
    Byung Ihn Choi
    Investigational New Drugs, 2013, 31 (5) : 1397 - 1397
  • [6] Quantification of Antiangiogenic and Antivascular Drug Activity by Kinetic Analysis of DCE-MRI Data
    Ferl, G. Z.
    Port, R. E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (01) : 118 - 124
  • [7] Antiangiogenic Agents and Vascular Disrupting Agents for the Treatment of Lung Cancer A Review
    Clement-Duchene, Christelle
    Wakelee, Heather
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (01) : 129 - 139
  • [8] Measurement of tumor vascular integrity changes in an orthotopic glioma model in rats induced by antiangiogenic treatment using DCE-MRI
    Provent, Peggy
    de Boisferon, Marc Hillairet
    Koob, Zina
    Bichat, Francis
    Tizon, Xavier
    CANCER RESEARCH, 2012, 72
  • [9] Are Complex DCE-MRI Models Supported by Clinical Data?
    Duan, Chong
    Kallehauge, Jesper F.
    Bretthorst, G. Larry
    Tanderup, Kari
    Ackerman, Joseph J. H.
    Garbow, Joel R.
    MAGNETIC RESONANCE IN MEDICINE, 2017, 77 (03) : 1329 - 1339
  • [10] Contrasting the vascular response to sunitinib as measured by DCE-CT, DCE-MRI, and DCE-US
    Hudson, John M.
    Williams, Ross
    Bailey, Colleen
    Kiss, Alex
    Milot, Laurent M.
    Atri, Mostafa
    Stanisz, Greg J.
    Burns, Peter N.
    Bjarnason, Georg A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345